dentocaine 40mg/0,005 mg/ml süstelahus
inibsa dental s.l. - artikaiin+epinefriin (adrenaliin) - süstelahus - 40mg+0,005mg 1ml 1.8ml 50tk
alcaine silmatilgad, lahus
alcon farmaceutika d.o.o. - proksümetakaiin - silmatilgad, lahus - 5mg 1ml 15ml 1tk
septanest süstelahus kolbampullis
septodont - artikaiin+epinefriin (adrenaliin) - süstelahus kolbampullis - 40mg+0,005mg 1ml 1.7ml 400tk; 40mg+0,005mg 1ml 1.7ml 200tk; 40mg+0,005mg 1ml 1.7ml 50tk
dentocaine 40mg/0,01 mg/ml süstelahus
inibsa dental s.l. - artikaiin+epinefriin (adrenaliin) - süstelahus - 40mg+0,01mg 1ml 1.8ml 100tk; 40mg+0,01mg 1ml 1.8ml 50tk
septanest forte süstelahus kolbampullis
septodont - artikaiin+epinefriin (adrenaliin) - süstelahus kolbampullis - 40mg+0,01mg 1ml 1.7ml 50tk
tot'hema suukaudne lahus
laboratoire innotech international - raud(ii)glükonaat+mangaanglükonaat+vaskglükonaat - suukaudne lahus - 5mg+0,133mg+0,07mg 1ml 10ml 20tk
celdoxome pegylated liposomal
yes pharmaceutical development services gmbh - doksorubitsiini vesinikkloriid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastilised ained - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).
metex süstelahus pen-süstlis
medac gesellschaft für klinische spezialpräparate mbh - metotreksaat - süstelahus pen-süstlis - 27,5mg 0.55ml 0.55ml 5tk; 27,5mg 0.55ml 0.55ml 12tk; 27,5mg 0.55ml 0.55ml 1tk; 27,5mg 0.55ml 0.55ml 4tk; 27,5mg 0.55ml 0.55ml 6tk; 27,5mg 0.55ml 0.55ml 2tk; 27,5mg 0.55ml 0.55ml 11tk
metex süstelahus pen-süstlis
medac gesellschaft für klinische spezialpräparate mbh - metotreksaat - süstelahus pen-süstlis - 30mg 0.6ml 0.6ml 2tk; 30mg 0.6ml 0.6ml 1tk; 30mg 0.6ml 0.6ml 12tk; 30mg 0.6ml 0.6ml 5tk; 30mg 0.6ml 0.6ml 4tk; 30mg 0.6ml 0.6ml 14tk; 30mg 0.6ml 0.6ml 6tk; 30mg 0.6ml 0.6ml 24tk; 30mg 0.6ml 0.6ml 10tk; 30mg 0.6ml 0.6ml 11tk